SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+1.67 (+2.37%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close70.34
Bid0.00 x 1000
Ask0.00 x 900
Day's Range68.71 - 72.78
52 Week Range47.75 - 84.37
Avg. Volume1,140,367
Market Cap11.532B
Beta (3Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-1.06
Earnings DateFeb 4, 2019 - Feb 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est80.36
Trade prices are not sourced from all markets
  • 5 Biotech Stocks That Could Face M&A Next!
    InvestorPlace6 days ago

    5 Biotech Stocks That Could Face M&A Next!

    Biotech stocks are already making some big waves this year. That's because M&A activity is already surging. Drawn by some big-time values, some of the world's biggest pharmaceutical firms have gone shopping for beaten-down biotech bargains. Already, we've seen Bristol-Meyers (NYSE:BMY) score Celgene (NASDAQ:CELG) for a cool $74 billion in a game-changing acquisition. More recently, Eli Lilly (NYSE:LLY) announced that it was pushing harder into cancer treatments with an $8 billion offer for Loxo Oncology (NASDAQ:LOXO). The question on everyone's minds is "who is next?" InvestorPlace - Stock Market News, Stock Advice & Trading Tips With plenty of biotech stocks still trading for peanuts and coffers overflowing at the major pharma's, more M&A activity is guaranteed. And while betting on a buyout may be a fool's errand, there are plenty of biotech stocks out there are on my best stocks to invest in list anyway. A buyout would be icing on the cake. * Morgan Stanley: 7 Risky Stocks to Sell Now But which ones have the potential to snagged up because they are so good? Here are five biotech stocks that could be buy-out candidates. Source: Shutterstock ### Seattle Genetics (SGEN) With oncology and cancer on the minds of many of the biggest names pharma, biotech stock Seattle Genetics (NASDAQ:SGEN) could once again be in play. SGEN has one drug available for patients -- Adcetris -- which is used to treat Stage III/IV classical Hodgkin lymphoma. Sales of Adcetris continue to grow rapidly. In the last reported quarter, revenues for the drug jumped by over 60% year-over-year. Even better is that number of indications, combinations and other uses for Adcetris have grown like weeds. SGEN continue to rack up more approvals and "breakthrough" designations for the drug. All of this has only made the medicine more lucrative for the biotech stock. As if that wasn't enough for big pharma to be salivating at the firm, Seattle Genetics has been able to pivot its technology towards other forms of cancer. The firm has numerous drugs targeting urothelial, cervical, breast and multiple myeloma cancer varieties. Here again, SGEN has been quite successful in moving its drugs through the FDA's hoops. Given growing sales of Adcetris and its heavy-duty cancer-focused pipeline, any biopharma looking to make a splash in oncology would seriously be considering SGEN stock. With a market cap of just over $11 billion, Seattle Genetics could one of the next biotech stocks to be bought out. Source: Shutterstock ### Agios Pharmaceuticals (AGIO) Keeping with the cancer buy-out theme, Agios Pharmaceuticals (NASDAQ:AGIO) makes an intriguing biotech buyout candidate. AGIO has two cancer therapies on the market. Its latest, Tibsovo, has been approved for those acute myeloid leukemia patients with an IDH1 mutation. The other -- Idhifa -- is for acute myeloid leukemia patients who also test positive for an IDH2 mutation. The firm basically has a one-two punch for this specific variety of leukemia. And while the drugs are new, prescriptions are growing, with Tibsovo seeing a 100% quarter-over-quarter increase in its short life span. That makes it a buyout candidate alone. Tibsovo is wholly owned by Agios. However, the real kicker is that Idhifa came via a partnership with Celgene. Celgene -- soon to be Bristol Meyers -- must continue to pay royalties on sales from the drug via a tiered structure that gets into the mid-teens. Given its buyout of CELG, BMY may just want to control the whole pie, and with AGIO's market cap sitting at just over $3 billion, it's an easy pill to swallow. And with the two medicines, BMY would be getting a healthy pipeline of additional cancer therapies as well as some rare disease work for a song. * 10 Stocks You Can Set and Forget (Even In This Market) Given that, there's a good chance that AGIO gets the nod. No wonder why shares have jumped higher since both CELG's and LOXO's buyout bids. Source: Shutterstock ### Jazz Pharmaceuticals (JAZZ) It's very rare to find biotech stocks trading for bargain-basement valuations. But that's just what is happening at Jazz Pharmaceuticals (NASDAQ:JAZZ). Today, you can snag JAZZ stock for forward P/E of under 10. JAZZ has five drugs on the market, with narcolepsy drug Xyrem being a blockbuster. Sales of Xyrem continue to grow and are expected to surpass $1.4 billion this year. At the same time, its portfolio of hematology/oncology drugs are proven to be winners as well and are helping JAZZ realize a double-digit EPS growth rate. Acute myeloid leukemia treatment Vyxeos, which only launched last year, is set to pull in roughly $100 million in sales for the full year 2018 and more than $200 million this year. Adding to this is JAZZ's pending March approval for its new drug covering excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Another late-stage candidate for cataplexy in narcolepsy should hit regulatory approval at the end of the year. With a rich drug portfolio and pipeline, JAZZ is a rarity among biotech stocks. It's profitable -- so much so that the firm has authorized a $400 million buyback program. That's after it already repurchased over $600 million in shares. Analysts estimate that a dividend could even be coming next. Featuring a market cap of less than $8 billion, JAZZ would be an easy and profitable tuck-in for almost any big pharma stock. Source: Shutterstock ### Neurocrine Biosciences (NBIX) A rare miss for Neurocrine Biosciences (NASDAQ:NBIX) sent shares crashing this year and left the firm with a $7.5 billion market cap. But NBIX's pain could end up being AbbVie's (NASDAQ:ABBV) gain. Over the summer, NBIX and ABBV received an FDA approval for their drug Orilissa, which is used in the treatment of pain associated with endometriosis. The drug is currently wrapping up trials for the treatment of uterine fibroids. Analysts think the drug has blockbuster potential with annual sales of around $1 billion. On its own, NBIX has a blockbuster in Ingrezza. The drug is used to treat tardive dyskinesia -- which is marked by jerky movements of the face and body out of a patient's control. The problem is tardive dyskinesia is a side effect of many depression, schizophrenia and other mental health drugs. This is a huge market, and Ingrezza sales are taking off. Management at Neurocrine estimates that they'll be able to pull in over $400 million in Ingrezza sales in 2018. And NBIX has a full pipeline of other drugs in various stages of trials. With a buyout, ABBV gets full access to Orilissa without royalty and milestone fees for future indications. Secondly, Ingrezza is quickly becoming a major money marker for NBIX. That would fill a nice hole in AbbVie's revenue stream and would help pay for the deal over the long haul. * The 7 Best Stocks in the Entrepreneur Index All in all, given its low market cap, hefty cash balance and marketed drugs, AbbVie may end up swallowing NBIX whole. Source: Shutterstock ### BioMarin Pharmaceutical (BMRN) When politicians and pundits often talk about the high price of drugs and mention therapies costing more than $400,000 per year, odds are, they are talking about rare and orphan diseases. For biotech stocks, targeting these diseases -- which sometimes can affect very small population sizes -- it can mean plenty of long-term revenues down the road. Given the research required to crack these afflictions, the high drug prices are more than justified. BioMarin (NASDAQ:BMRN) is one biotech stock that has made rare diseases its specialty. The firm has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. Rare disease medications come with longer exclusivity rights and by focusing here, BMRN basically ensures patient protection versus generic competition. At the same time, these drugs pull in some big-time revenues. For example, this year, BioMarin expects to make more than $1.5 billion in sales with its top five drugs. Meanwhile, the biotech stocks pipeline is rich as well with drugs for hemophilia and sanfilippo in late-stage trials. Because of its focus, profitability and rich rare disease pipeline, BioMarin has long been considered a buy candidate. With big pharma finally starting to spend some dough, that takeover may finally happen. At the time of writing, Aaron Levitt had a long position in CELG and JAZZ ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 5 Biotech Stocks That Could Face M&A Next! appeared first on InvestorPlace.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    # Seattle Genetics Inc ### NASDAQ/NGS:SGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding SGEN is favorable, with net inflows of $9.31 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Seattle Genetics-occupied Bothell property fetches $34 million
    American City Business Journals14 days ago

    Seattle Genetics-occupied Bothell property fetches $34 million

    Equus Capital Partners Ltd. said it has acquired the three-building Highlands Campus Tech Centre in Bothell. Philadelphia-headquartered Equus paid New York City-based Investcorp just over $33.55 million, according to public records. Investcorp acquired the property in 2014, as part of a larger $250 million purchase.

  • Hedge Funds Are Dumping Seattle Genetics, Inc. (SGEN)
    Insider Monkey26 days ago

    Hedge Funds Are Dumping Seattle Genetics, Inc. (SGEN)

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]

  • Business Wire28 days ago

    Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

    Seattle Genetics, Inc. announced today that management will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time.

  • Understanding Seattle Genetics’ Operational Performance
    Market Realistlast month

    Understanding Seattle Genetics’ Operational Performance

    How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.

  • What Seattle Genetics’ Bottom-Line Trend Indicates
    Market Realistlast month

    What Seattle Genetics’ Bottom-Line Trend Indicates

    Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.

  • How’s Seattle Genetics Positioned?
    Market Realistlast month

    How’s Seattle Genetics Positioned?

    How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

  • GlobeNewswirelast month

    Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose — Future Expectations, Projections Moving into 2019

    NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • Business Wirelast month

    Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting

    -Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma-

  • Business Wire2 months ago

    Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting

    -Initial Data Reported from Phase 2 Clinical Trial in Relapsed Primary Mediastinal Large B-Cell Lymphoma-

  • Seattle Genetics opening Bay Area office to attract talent it can't lure to Bothell
    American City Business Journals2 months ago

    Seattle Genetics opening Bay Area office to attract talent it can't lure to Bothell

    It's the Bothell-based company's first U.S. office outside the Puget Sound region and may be a stepping stone to further expansion around the country.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • Business Wire2 months ago

    Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting

    Seattle Genetics, Inc. announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology  Annual Meeting in San Diego, Calif. The program will feature the phase 3 ECHELON-2 trial as well as other key data from the meeting.

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • What You Must Know About Seattle Genetics Inc’s (NASDAQ:SGEN) Financial Health
    Simply Wall St.2 months ago

    What You Must Know About Seattle Genetics Inc’s (NASDAQ:SGEN) Financial Health

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Seattle Genetics Inc (NASDAQ:SGEN), with a market capitalization of US$9.2b, rarely draw their attention from the investing Read More...

  • Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session
    Zacks2 months ago

    Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session

    Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 6% on Friday, amid huge volumes.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Amarin and Seattle Genetics

    NEW YORK, NY / ACCESSWIRE / November 19, 2018 / U.S. equities finished mostly in the green on Friday as investors digested comments from President Donald Trump, expressing confidence in resolving the current ...

  • MarketWatch2 months ago

    Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment

    Shares of Seattle Genetics Inc. rose more than 6% Friday, after the company said it had received a new approval for its Adcetris therapy as a treatment for previously untreated peripheral T-Cell Lymphoma. The U.S. Food and Drug Administration approved Adcetris in combination with CHP chemotherapy based on the successful outcome of its phase 3 ECHELON-2 clinical trial, the company said in a statement. The FDA used a new approval pathway that allowed it to come just two weeks after the company submitted data and just under two months since it announced topline data. "While this approval was widely anticipated given the Overall Survival benefit and positive trial (ECHELON-2), we believe SGEN shares will react favorably given that it suggests PTCL revenues are likely to start in Q4, and also dispels any risk from the upcoming American Society of Hematology (ASH) presentation, especially in regards to the broader, non-ALCL (anaplastic large cell lymphoma ) cohort, which were included in this label," said Leerink analyst Andrew Berens. Leerink was previously expected revenue to start in 2019. It is the sixth FDA-approved indication for Adcetris. Shares have gained 7% in 2018, while the S&P 500 has gained 2%.

  • Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
    Zacks2 months ago

    Seattle Genetics' Adcetris Gets Breakthrough Therapy Status

    Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.